ALK and non-small cell lung carcinoma: Of 1106 patients with ALK‐positive NSCLC treated with crizotinib across PROFILE 1005 and PROFILE 1007, a total of 1053 (84% from PROFILE 1005 and 16% from PROFILE 1007) had both baseline and postbaseline HRs recorded and were included in this retrospective analysis.